{"id":"NCT02755597","sponsor":"AbbVie","briefTitle":"A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy","officialTitle":"A Phase 3, Multicenter, Randomized, Double Blind Study of Bortezomib and Dexamethasone in Combination With Either Venetoclax or Placebo in Subjects With Relapsed or Refractory Multiple Myeloma Who Are Sensitive or Naïve to Proteasome Inhibitors","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-07-11","primaryCompletion":"2021-03-15","completion":"2022-08-15","firstPosted":"2016-04-29","resultsPosted":"2023-08-22","lastUpdate":"2023-08-22"},"enrollment":291,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Relapsed/Refractory Multiple Myeloma"],"interventions":[{"type":"DRUG","name":"Venetoclax","otherNames":["VENCLEXTA","VENCLYXTO"]},{"type":"DRUG","name":"Bortezomib","otherNames":["Velcade"]},{"type":"DRUG","name":"Dexamethasone","otherNames":[]},{"type":"DRUG","name":"Placebo for venetoclax","otherNames":[]}],"arms":[{"label":"Venetoclax + Bortezomib and Dexamethasone","type":"EXPERIMENTAL"},{"label":"Placebo + Bortezomib and Dexamethasone","type":"PLACEBO_COMPARATOR"}],"summary":"This was a Phase 3, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of venetoclax plus bortezomib and dexamethasone in participants with relapsed or refractory multiple myeloma who are considered sensitive or naïve to proteasome inhibitors and received 1 to 3 prior lines of therapy for multiple myeloma.","primaryOutcome":{"measure":"Progression-free Survival (PFS)","timeFrame":"Median duration of follow-up was 28.6 months for the venetoclax group and 28.6 months for the placebo group","effectByArm":[{"arm":"Venetoclax + Bortezomib and Dexamethasone","deltaMin":23.2,"sd":null},{"arm":"Placebo + Bortezomib and Dexamethasone","deltaMin":11.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"=0.012"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":97,"countries":["United States","Australia","Brazil","Canada","France","Germany","Hungary","Ireland","Italy","Japan","Russia","South Korea","Spain","Taiwan","Ukraine","United Kingdom"]},"refs":{"pmids":["40587991","33129376"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":115,"n":193},"commonTop":["DIARRHOEA","CONSTIPATION","NAUSEA","FATIGUE","THROMBOCYTOPENIA"]}}